Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (131-140 of 303) with videos related to

Pageof 31
Sort By:
Cancer|June 22, 2010
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapySeung Tae Kim, Jeeyun Lee, Jeong-Hoon Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2010
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastasesJong-Mu Sun, Jin Seok Ahn, Soohyeon Lee, et al.
Nature Communications|September 21, 2019
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number loadHyunchul Jung, Hong Sook Kim, Jeong Yeon Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2018
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLCYoujin Kim, Boram Lee, Joon Ho Shim, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2009
Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapyJong-Mu Sun, Tae Sung Kim, Jeeyun Lee, et al.
Nature Communications|February 21, 2020
Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicityKwoneel Kim, Hong Sook Kim, Jeong Yeon Kim, et al.
Scientific Reports|March 21, 2020
Surgically Resected Esophageal Squamous Cell Carcinoma: Patient Survival and Clinicopathological Prognostic FactorsDong Young Jeong, Kyung Soo Lee, Joon Young Choi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2019
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencingHong Sook Kim, Hongui Cha, Jinho Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2010
Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapyJong-Mu Sun, Joon Oh Park, Young-Woong Won, et al.
Journal of Cancer Research and Clinical Oncology|June 17, 2010
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patientsJong-Mu Sun, Young-Woong Won, Seung Tae Kim, et al.
Pageof 31

Showing results (131-140 of 303) with videos related to

Sort By:
Pageof 31
Cancer|June 22, 2010
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapySeung Tae Kim, Jeeyun Lee, Jeong-Hoon Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2010
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastasesJong-Mu Sun, Jin Seok Ahn, Soohyeon Lee, et al.
Nature Communications|September 21, 2019
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number loadHyunchul Jung, Hong Sook Kim, Jeong Yeon Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2018
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLCYoujin Kim, Boram Lee, Joon Ho Shim, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2009
Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapyJong-Mu Sun, Tae Sung Kim, Jeeyun Lee, et al.
Nature Communications|February 21, 2020
Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicityKwoneel Kim, Hong Sook Kim, Jeong Yeon Kim, et al.
Scientific Reports|March 21, 2020
Surgically Resected Esophageal Squamous Cell Carcinoma: Patient Survival and Clinicopathological Prognostic FactorsDong Young Jeong, Kyung Soo Lee, Joon Young Choi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2019
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencingHong Sook Kim, Hongui Cha, Jinho Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2010
Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapyJong-Mu Sun, Joon Oh Park, Young-Woong Won, et al.
Journal of Cancer Research and Clinical Oncology|June 17, 2010
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patientsJong-Mu Sun, Young-Woong Won, Seung Tae Kim, et al.
Pageof 31